

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

IN RE: OZEMPIC (SEMAGLUTIDE) PATENT LITIGATION	)) MDL No. 22-MD-3038 (CFC)) ANDA CASE)))
NOVO NORDISK INC. and NOVO NORDISK A/S,	)) ~~CONFIDENTIAL~~) ~~INFORMATION SUBJECT TO~~) ~~PROTECTIVE ORDER~~)
Plaintiffs,	))
v.	) C.A. No. 22-294 (CFC)) CONSOLIDATED
RIO BIOPHARMACEUTICALS INC., et al.,	) ANDA CASE))
Defendants.	)

**PLAINTIFFS' SECOND AMENDED DISCLOSURES TO DEFENDANTS
DR. REDDY'S LABORATORIES, LTD. AND DR. REDDY'S
LABORATORIES, INC. PURSUANT TO RULE 26(a)(1) OF THE
FEDERAL RULES OF CIVIL PROCEDURE**

Pursuant to Fed. R. Civ. P. 26(a)(1), Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S (collectively, "Plaintiffs"), by their attorneys, hereby provide the following second amended disclosures to Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, "DRL").

These disclosures are based upon information reasonably and presently available to Plaintiffs, while discovery is ongoing. Plaintiffs reserve the right to supplement and/or amend these disclosures as necessary upon further investigation

Individual	Address	Subject
Christian Peter Enggaard	Fenwick & West LLP	Certain information concerning research and development for Ozempic [®] , including the subject matter described in U.S. Patent Nos. 8,920,383 and 9,775,953.
Christine Bjørn Jensen	Fenwick & West LLP	Certain information concerning research and development for Ozempic [®] , including the subject matter described in U.S. Patent No. 10,335,462.
Stephanie DeChiaro	Fenwick & West LLP	Certain information concerning regulatory matters for Ozempic [®] .
Vanessa Costain	Fenwick & West LLP	Certain information concerning sales and marketing of Ozempic [®] .
All persons knowledgeable	Dr. Reddy's Laboratories, Ltd. (Door No. 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500034, India)	The DRL Product; research and development of the DRL Product; the DRL ANDA; DRL's decision to develop the DRL Product and file the DRL ANDA; subject matter disclosed and claimed in U.S. Patent Nos. 8,129,343; 8,920,383; 9,775,953; and 10,335,462.

CERTIFICATE OF SERVICE

I hereby certify that on July 28, 2023, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on July 28, 2023, upon the following in the manner indicated:

Dominick T. Gattuso, Esquire
HEYMAN ENERIO GATTUSO
& HIRZEL LLP
300 Delaware Avenue, Suite 200
Wilmington, DE 19801
*Attorneys for Defendants Dr. Reddy's
Laboratories, Ltd. and Dr. Reddy's
Laboratories, Inc.*

VIA ELECTRONIC MAIL

Jovial Wong, Esquire
Sharon Lin, Esquire
WINSTON & STRAWN LLP
1901 L Street N.W.
Washington DC 20036
*Attorneys for Defendants Dr. Reddy's
Laboratories, Ltd. and Dr. Reddy's
Laboratories, Inc.*

VIA ELECTRONIC MAIL

Alison M. King, Esquire
WINSTON & STRAWN LLP
35 West Wacker Drive
Chicago, IL 60601-9703
*Attorneys for Defendants Dr. Reddy's
Laboratories, Ltd. and Dr. Reddy's
Laboratories, Inc.*

VIA ELECTRONIC MAIL

/s/ Travis J. Murray

Travis J. Murray (#6882)